Cabozantinib is a targeted therapy used to treat many forms of cancers. Prof. Robert Jones (University of Glasgow, Scotland, United Kingdom) discusses the rationale, design, and findings of the randomised phase 2 ATLANTIS trial, of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma.
Questions:
- What is the rationale for the use of cabozantinib in the treatment of metastatic urothelial cancer? (00:12-01:05)
- What makes the ATLANTIS clinical trial design unique? (01:05-02:32)
- What were the efficacy and safety findings of the ATLANTIS cabozantinib comparison? (02:32-03:40)
The abstract entitled: ‘A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison’ was presented at the ASCO annual meeting, June 3-7, 2022.
Disclosures: Robert Jones has received grant/research support from Astellas, AstraZeneca, Clovis, Exelixis and Roche. He is on the Advisory Board for Astellas, AstraZeneca, BMS, Clovis, Merck Serono, MSD, Pfizer, QED and Roche. He has received honoraria/honorarium from Astellas, AstraZeneca, BMS, Clovis, Merck Serono, MSD, Pfizer and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
